PMID- 7508509
OWN - NLM
STAT- MEDLINE
DCOM- 19940317
LR  - 20171116
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 20
IP  - 11
DP  - 1993 Nov
TI  - B cell hyperactivity is a function of T cell derived cytokines in systemic lupus 
      erythematosus.
PG  - 1885-91
AB  - OBJECTIVE: T cell abnormalities and abnormal production of cytokines is a key 
      event of B cell hyperactivity and antibody synthesis in systemic lupus 
      erythematosus (SLE). We investigated T cell function and role of interleukin 4 
      (IL-4) and IL-6 in B cell induced Ig synthesis from SLE. METHODS: Phenotypes and 
      expression of activation antigens on T cells and monocytes was determined by 
      specific monoclonal antibodies using indirect immunofluorescence technique. IL-4, 
      IL-6 and tumor necrosis factor-alpha (TNF alpha) assays and in vitro Ig synthesis 
      was carried out by enzyme linked immunosorbent assays. RESULTS: CD25, CD38 and 
      CD71 expressing T cells and monocytes were increased in circulation of patients 
      with SLE. Patients with SLE associated with prominent clinical presentation like 
      lymphadenopathy had a higher percentage of gamma delta T cells in blood. 
      CD4+CD29+ T cell subsets, which were the major T cells secreting IL-6, were 
      increased in the circulation and provide effective helper function to B cells in 
      their enhanced in vitro Ig synthesis in SLE. CONCLUSION: Our results demonstrate 
      that CD4+CD29+ T cell subsets produced elevated levels of IL-6 in SLE and that 
      IL-6 overproduction may contribute to the B cell hyperactivity in enhanced 
      antibody synthesis characteristic of this autoimmune disease.
FAU - al-Janadi, M
AU  - al-Janadi M
AD  - Department of Internal Medicine (Rheumatology), King Saud University, College of 
      Medicine, Abha, Saudi Arabia.
FAU - Raziuddin, S
AU  - Raziuddin S
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation)
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (CD4 Antigens)
RN  - 0 (CD71 antigen)
RN  - 0 (Cytokines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Integrin beta1)
RN  - 0 (Interleukin-6)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Receptors, Transferrin)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207137-56-2 (Interleukin-4)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
RN  - EC 3.2.2.5 (ADP-ribosyl Cyclase)
RN  - EC 3.2.2.5 (CD38 protein, human)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase
MH  - ADP-ribosyl Cyclase 1
MH  - Adult
MH  - Antigens, CD/analysis
MH  - Antigens, Differentiation/analysis
MH  - Antigens, Differentiation, B-Lymphocyte/analysis
MH  - B-Lymphocytes/chemistry/*pathology/*physiology
MH  - CD4 Antigens/analysis
MH  - Cytokines/analysis/*metabolism/*physiology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - Immunoglobulin G/metabolism
MH  - Integrin beta1
MH  - Interleukin-4/analysis/metabolism/physiology
MH  - Interleukin-6/analysis/metabolism/physiology
MH  - Leukocyte Common Antigens/analysis
MH  - Lupus Erythematosus, Systemic/immunology/*metabolism/*pathology
MH  - Lymphocyte Activation
MH  - Membrane Glycoproteins
MH  - Monocytes/immunology/metabolism/pathology
MH  - Phenotype
MH  - Receptors, Interleukin-2/analysis
MH  - Receptors, Transferrin
MH  - T-Lymphocyte Subsets/metabolism/physiology
MH  - T-Lymphocytes/immunology/*metabolism/pathology
MH  - Tumor Necrosis Factor-alpha/analysis/metabolism/physiology
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol. 1993 Nov;20(11):1885-91.